ALNYLAM PHARMACEUTICALS, INC. 8K

Alnylam reported strong Q2 2026 revenue and a return to profitability driven by rapid growth of its TTR franchise, while modestly lowering full‑year 2026 TTR and total net product revenue guidance and advancing key pipeline, AI, and commercialization partnerships.

Alnylam Pharmaceuticals, Inc. reported strong second quarter 2026 financial results, with total revenues rising 67% year over year to $1.29 billion and net product revenues up 74% to $1.17 billion, driven largely by 89% growth in its transthyretin (TTR) franchise (AMVUTTRA and ONPATTRO) to $1.03 billion, while simultaneously lowering full‑year 2026 TTR net product revenue guidance to $4.2–$4.5 billion and total net product revenue guidance to $4.7–$5.1 billion to reflect more normalized second‑line AMVUTTRA demand in the U.S. ATTR‑CM market. The company highlighted multiple pipeline and strategic milestones, including Phase 2 starts for ALN-6400 in von Willebrand disease and mivelsiran in Down syndrome-associated Alzheimer’s disease, additional data from the HELIOS-B Phase 3 trial of vutrisiran in ATTR-CM, progression of its Alzheimer’s and obesity programs, an exclusive commercialization agreement with BeOne Medicines for AMVUTTRA in China, AI-driven collaborations with Inceptive Nucleics and a large California health system to enhance RNAi discovery and ATTR-CM detection, expansion of its Komodo Health partnership, and upcoming data milestones such as initial Phase 1 results for ALN-HTT02 in Huntington’s disease. Alnylam also reported a swing to GAAP profitability (Q2 2026 GAAP net income of $164.5 million vs. a $72.2 million loss in Q2 2025), increased R&D and SG&A spending to support late-stage trials and the AMVUTTRA launch, and a strengthened balance sheet with $3.3 billion in cash, cash equivalents, and marketable securities as of June 30, 2026.

Filing Facts

CIK

1178670

Ticker

ALNY

Form

8K

Source Type

fda

Accession

0001178670-26-000060

Alert Tier

7